Pharma Marketing News Vol. 9, #5: May 2010
Welcome to the MAY 2010 issue of Pharma Marketing News.
Pharma Marketing News Vol. 9, #5: May 2010
Welcome to the MAY 2010 issue of Pharma Marketing News.
NAMI’s Pharma Funders – Serial Off-label Promoter Astrazeneca Tops the List
The National Alliance on Mental Illness (NAMI) until recently was reluctant to reveal the source of its funding. But thanks to Sen. Grassley we...
How NOT to Solicit Adverse Medical Event Reports
My Twitter and real-life pal Fabio Gratton (@skypen) -- Co-founder & Chief Innovation Officer of Ignite Health -- sent out this tweet today:
New Web...
Social Media and the Future of Adverse Event Reporting
I am speaking tomorrow at the World Drug Safety Congress in Washington, DC. The title of my presentation is "Social Media and the Future...
Pharma’s ObamaCare Math: It All Adds Up, But…
Drug companies are already claiming a loss of income due to costs related to the new U.S. health-care overhaul (aka, "ObamaCare"). First, Lilly claimed...
Pharma “Social Networks”: Close But No Cigar Award
If you are a regular reader of Pharma Marketing Blog, you know that I generally do not like awards that are given to pharmaceutical...
Voltaren “Adherence Email” Gets FDA Warning Letter: Is It Justified?
As of April 15, 2010, FDA's Division of Drug Marketing, Advertising and Communications (DDMAC) sent out 5 "notice of violation" (aka "warning") letters to...
Pre-Screening, Post-Screening, or No Screening at All – What’s the Best Moderation Practice for...
As more and more pharmaceutical companies launch social networking platforms associated with their brands, some will allow users (consumers, patients, physicians, and the anonymous...
If Patients Know Best, then Patient Social Networks Can Help Capture and Report AEs
A recent article published in the New York Times caught my attention. The article -- "In Reporting Symptoms, Don’t Patients Know Best?" (find it...
